CENTOGENE NV (CNTG)
NL0014040206 - Common Stock
CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners
CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”), the...
CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology
CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology
Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further...
CENTOGENE Receives Delisting Notice From Nasdaq
CENTOGENE Receives Delisting Notice From Nasdaq
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven...
CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors
Initial data from largest international Parkinson’s disease patient cohort shows approximately 90% of these genetically confirmed patients had variants in...
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in...
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday and we have them covered with our breakdown of all the latest news this morning!
CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
Reported Full Year 2023 total revenues of 2% growth at €48.5 millionSecured approximately USD 20 million – strengthening cash position and expanding...
CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
Expanding Relationship With Lifera, a Biopharma Company Owned by the PIF
CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
Expanding Relationship With Lifera, a Biopharma Company Owned by the PIF...
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies amend existing drug...
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
Fueling the diagnosis of over 2,500 rare and neurodegenerative diseases, more than 300 peer-reviewed publications, and 48 pharma collaborations
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
Fueling the diagnosis of over 2,500 rare and neurodegenerative diseases, more than 300 peer-reviewed publications, and 48 pharma collaborations...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Friday is here and we're breaking down the biggest pre-market stock movers that traders need to know about this morning!
CENTOGENE Receives Nasdaq Non-Compliance Notice
CENTOGENE Receives Nasdaq Non-Compliance Notice
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notification letter dated March 27, 2024, from the Nasdaq Stock Market LLC Listing Qualifications Department, indicating that the Company was not in compliance with the minimum bid price requirement set forth in Rule 5450(a)(1) of the Nasdaq Listing Rules since the closing bid price for the Company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days (from February 12 through March 26, 2024). Nasdaq Rule 5450(a)(1) requires the shares to maintain a minimum bid price of US$1.00 per share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the shares is below US$1.00 for a period of 30 consecutive business days.
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) CAMBRIDGE, Mass. and...
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected...
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities
CENTOGENE Explores Strategic Alternatives
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities...
CENTOGENE Explores Strategic Alternatives
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life...
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development...
CENTOGENE Receives French Research Tax Credit Accreditation
Partners able to claim up to 30% tax relief
CENTOGENE Receives French Research Tax Credit Accreditation
Partners able to claim up to 30% tax relief...
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
Collaboration to accelerate research to determine role of GBA gene
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
Collaboration to accelerate research to determine role of GBA gene...